Vertical Bone Augmentation With Simultaneous Implant Placement Using Particulate Mineralized Bone and Mesenchymal Stem Cells: A Preliminary Study in Rabbit

Khojasteh, Arash; Eslaminejad, Mohamadreza Baghaban; Nazarian, Hamid; Morad, Golnaz; Dashti, S. Ghazaleh; Behnia, Hossein; Stevens, Mark R.

doi:10.1563/aaid-joi-d-10-00206

Cited by 35 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; Khojasteh et al. ). Although, to the best of our knowledge, this is the first experimental rabbit study reporting on early bone growth for vertical augmentation using membrane procedures in combination with rhPDGF‐soaked and implant‐fixed DBB‐blocks.…”

Section: Discussionmentioning

confidence: 98%

Influence of a collagen membrane and recombinant platelet‐derived growth factor on vertical bone augmentation in implant‐fixed deproteinized bovine bone – animal pilot study

Kämmerer

Palarie

Schiegnitz

et al. 2012

Clinical Oral Implants Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Influence of a collagen membrane and recombinant platelet‐derived growth factor on vertical bone augmentation in implant‐fixed deproteinized bovine bone – animal pilot study

Kämmerer

Palarie

Schiegnitz

et al. 2012

Clinical Oral Implants Res

View full text Add to dashboard Cite

show abstract

“…Authors have used MSCs with different kind of ceramics for bone engineering in several previous experiments 10–14, 33, 34. The use of MSCs with HA/TCP biphasic scaffold in 10 mm noncritical size dog mandibular defects revealed 65.78% BF, whereas natural bovine mineral with MSCs showed 44.9% BF 10.…”

Section: Discussionmentioning

confidence: 99%

The effect of PCL‐TCP scaffold loaded with mesenchymal stem cells on vertical bone augmentation in dog mandible: A preliminary report

et al. 2013

Self Cite

View full text Add to dashboard Cite

Polycaprolactone-tricalcium phosphate (PCL-TCP), a new composite scaffold, has been shown to facilitate early revascularization and speed up bone regeneration process. The objective of this study was to evaluate the effect of PCL-TCP seeded with mesenchymal stem cells (MSCs) on healing of the vertical bone critical sized defect in dog's mandible. Bone marrow aspirate from dog humerous was cultured and the stemness of the cells was examined by differentiation staining methods and flow cytometric analysis. Third passage subculture cells (5 × 10⁵ cells) were loaded on 20 × 10 × 10 mm³ and incubated for 48 h. The presence of MSCs in the pores was evaluated by scanning electron microscope. Bilateral mandibular premolar teeth were extracted in four dogs and the buccal and lingual bone plates were reduced to make a vertical defect. Cell-loaded scaffolds were fixed in right side and left side received pure PCL-TCP scaffolds as a control side defects. Histomorphometric analysis after 8 weeks of the scaffold implantation showed higher amount of lamellar bone in the test side (48.63%) than control side (17.27%) (p < 0.05).The results suggest that PCL-TCP may be an appropriate scaffold for loading MSCs in bone regeneration.

show abstract

“…In dogs, the largest improvements in indices of osteoblast activity were noted in a group undergoing transsutural distraction osteogenesis that received recombinant human bone morphogenic protein poly(lactic-co-glycolic) acid and fibrin sealant 5 days after operation as well as, in addition, recombinant human osteoprotegerin with fibrin sealant three weeks later [121]. Lastly, an allogenic bone, fibrin sealant, and mesenchymal stem cell combination was found to be significantly ( P < 0.05) better than controls without stem cells at both bone length and formation in a rabbit tibial model designed to assess vertical bone augmentation [122]. …”

Section: Fibrin Sealant Laboratory Literaturementioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

Background. Fibrin sealant became the first modern era material approved as a hemostat in the United States in 1998. It is the only agent presently approved as a hemostat, sealant, and adhesive by the Food and Drug Administration (FDA). The product is now supplied as patches in addition to the original liquid formulations. Both laboratory and clinical uses of fibrin sealant continue to grow. The new literature on this material also continues to proliferate rapidly (approximately 200 papers/year). Methods. An overview of current fibrin sealant products and their approved uses and a comprehensive PubMed based review of the recent literature (February 2012, through March 2013) on the laboratory and clinical use of fibrin sealant are provided. Product information is organized into sections based on a classification system for commercially available materials. Publications are presented in sections based on both laboratory research and clinical topics are listed in order of decreasing frequency. Results. Fibrin sealant remains useful hemostat, sealant, and adhesive. New formulations and applications continue to be developed. Conclusions. This agent remains clinically important with the recent introduction of new commercially available products. Fibrin sealant has multiple new uses that should result in further improvements in patient care.

show abstract

Vertical Bone Augmentation With Simultaneous Implant Placement Using Particulate Mineralized Bone and Mesenchymal Stem Cells: A Preliminary Study in Rabbit

Cited by 35 publications

References 37 publications

Influence of a collagen membrane and recombinant platelet‐derived growth factor on vertical bone augmentation in implant‐fixed deproteinized bovine bone – animal pilot study

Influence of a collagen membrane and recombinant platelet‐derived growth factor on vertical bone augmentation in implant‐fixed deproteinized bovine bone – animal pilot study

The effect of PCL‐TCP scaffold loaded with mesenchymal stem cells on vertical bone augmentation in dog mandible: A preliminary report

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Contact Info

Product

Resources

About